Download Lysbilde 1

Trans-Atlantic Cooperation
Technology Transfer Office
Director
Johan C. Haveland
Washington DC 03.12.04
University of Bergen
• 7 faculties
• +17 000 students
• 2 800 faculty and staff
• urban
• high quality research
• international collaborations
Profile
• research
• education
• communication
• marine environment
• international co-operation
Track Record and projects
•
•
•
•
2 spin-outs sold for $20M+ each
2 running spinouts with more than
$7M annual revenue
18 running spinouts
New patents
– Methane Hydrate (US based
oil company)
– Platform technology for bionano (tunnelling nano tubes)
– MR-imaging algorithm for
rapid pictures from MRiscanners
Hans-Herrmann Gerdes et. Al. –
TNTs published in Science
13.02.04
Establishing US biotech comp. in Bergen
•
•
•
Currently developing collaboration
model with a San Francisco
biotech company
– using IPR owned by biotech
– using unique UiB expertise
and positioning towards
translational medicine
– building Norwegian role in
international market
– capitalising on biotech’s
existing sales network
Goal: new joint-owned company in
Norway
Agreed Goal –
– Q2 2005: proof of concept;
– Q3 2005: start-up.
UniTargetingResearch
• Protein drugs: a $33 bn industry (growth 30%)
– Large product pipeline
– Considerably undersized production capacity
• UTR® technology: up to 30-fold production yields.
– Genetically engineered vectors for mammalian cell production
– Boosts secretion of proteins
• Also intracellular & membrane proteins: purify from
medium, not cells!
– Customers: biopharma, contract manufacturers, small biotech
• Validated for antibody production and gene therapy.
• Management and advisors from Serono, Eli Lilly, leading
academia.
• Raising €1-3 mln.
Novel Diagnostics
•
Test kit for early detection of colorectal cancer
– Emerging screening market Europe $6 billion
– Norway: 3000 kits sold
– Rollout plan for Europe
•
Acute phase detection of infectious disease
– Significantly improves $1,9 bn ELISA platform
– HIV: ongoing clinical trials South Africa
– Tuberculosis: ongoing clinical trials by
bioMerieux.
EIA
•
•
Management, executives from
Abbott Labs, Johnson & Johnson, Murex
Diagnostics, Wellcome Diagnostics (Now
GlaxoSmithKline)
Raising €3-10 mln, €3 placed
Amount
PlasmAcute®
NAT
10
HIV infected
20
MediMush
•
Biopharmaceuticals and nutraceuticals from
medicinal mushrooms, high end market: $2-3 bn
•
MediMush production (patented)
– Ingredients of superior quality, purity, and at a
fraction of current costs
• Key issues to supplement, nutraceuticals
suppliers
• Enables oral medicine delivery,
Sine Parmaceautical Company (China)
•
•
•
#1 Product (Lentinan), under validation by
General Nutrition Company (USA)
– Animal testing with US National Cancer
Institute and University of Louisiana.
Management from nutraceuticals business,
academia.
Raising €1-3 million
Shitake
Lentinan for
injection
Phases of commercialisation
Ideas
Project
Develop.
Seed
Services Venture
Sales/IPO
Material Transfer
Agreement
Capital
Capital
Industrial cooperation
IPR Management (external financing)
Idea - advising
Regional
TTO
Inc from
22.12.04
UiB, University
Hospital, Institte of
Marine
Research,Bergen
University
College, CMR,
NIFES
Service
providers/
researchers
ForInnva
InnoVest
Incubator
Start Up
Investment
Commercialisation
in growth - Resources
Project evaluation/Market identification
Scientific and Market Verification
Unique technology (patent search and filing)
Licensing vs start-up models…
Proof of Concept: Prototype
Sarsia Innovation
Seed Capital
Preseed funding
Meltzer Selection of ideas for commercialization
Foundation
Unifob Foundation
Main Challenges for Regional TTO
Ideas
Early
selection
citerias
Project
Develop.
Market
Evaluation
Pre-Seed
funding
Seed
Capital
Fewer
companies
Seed
Capital
Venture
Capital
Companies
ready for
VC
Venturekapital
Sales/IPO
Develop
internal
skills
Attract
capital
Trans-Atlantic Help
• TTO - Network for early stage
selection of ideas
• Understanding of VC
• US Network for licencing